Pullulan: A new cytoadhesive for cell-mediated cartilage repair

Stem Cell Research and Therapy

Volumn 6, Issue 1, 2015, Pages

  Bulman, Sarah E ^a,b   Coleman, Cynthia M ^a   Murphy, J Mary ^a   Medcalf, Nicholas ^c   Ryan, Aideen E ^a   Barry, Frank ^a  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b Smith and Nephew Research Centre   (United Kingdom)

^c LOUGHBOROUGH UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; DECTIN 2; ENDOGLIN; HERMES ANTIGEN; PULLULAN; THY 1 ANTIGEN; BIOMATERIAL; DECTIN-2, HUMAN; GLUCAN; LECTIN; TISSUE ADHESIVE;

ADIPOGENESIS; ADULT; ARTICLE; ARTICULAR CARTILAGE; BIOCOMPATIBILITY; CELL ADHESION; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CELL VIABILITY; CHONDROGENESIS; CONCENTRATION RESPONSE; CONTROLLED STUDY; EXPLANT; HUMAN; HUMAN CELL; HUMAN TISSUE; MESENCHYMAL STEM CELL; OSTEOARTHRITIS; PRIORITY JOURNAL; TISSUE REPAIR; ADOLESCENT; BIOSYNTHESIS; CARTILAGE; CELL CULTURE; CHONDROCYTE; CYTOLOGY; DRUG EFFECTS; MESENCHYMAL STROMA CELL; METABOLISM; PHYSIOLOGY; WOUND HEALING; YOUNG ADULT;

ADIPOGENESIS; ADOLESCENT; ADULT; BIOCOMPATIBLE MATERIALS; CARTILAGE; CELL ADHESION; CELLS, CULTURED; CHONDROCYTES; CHONDROGENESIS; GLUCANS; HUMANS; LECTINS, C-TYPE; MESENCHYMAL STROMAL CELLS; OSTEOARTHRITIS; TISSUE ADHESIVES; WOUND HEALING; YOUNG ADULT;

EID: 84928547281     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/s13287-015-0011-7     Document Type: Article

References (69)

1. Aigner T, McKenna L. Molecular pathology and pathobiology of osteoarthritic cartilage. Cell Mol Life Sci. 2002;59:5-18.
2. Henson FM, Bowe EA, Davies ME. Promotion of the intrinsic damage-repair response in articular cartilage by fibroblastic growth factor-2. Osteoarthritis Cartilage. 2005;13:37-44.
3. Goldring MB, Goldring SR. Osteoarthritis. J Cell Physiol. 2007;213:626-34.
4. Poole AR, Kobayashi M, Yasuda T, Laverty S, Mwale F, Kojima T, et al. Type II collagen degradation and its regulation in articular cartilage in osteoarthritis. Ann Rheum Dis. 2002;61 Suppl 2:ii78-81.
5. Chiang H, Jiang CC. Repair of articular cartilage defects: review and perspectives. J Formos Med Assoc. 2009;108:87-101.
6. Hunziker EB. The elusive path to cartilage regeneration. Adv Mater. 2009;21:3419-24.
7. Ashton BA, Allen TD, Howlett CR, Eaglesom CC, Hattori A, Owen M. Formation of bone and cartilage by marrow stromal cells in diffusion chambers in vivo. Clin Orthop Relat Res. 1980;151:294-307.
8. Goshima J, Goldberg VM, Caplan AI. The osteogenic potential of culture-expanded rat marrow mesenchymal cells assayed in vivo in calcium phosphate ceramic blocks. Clin Orthop Relat Res. 1991;262:298-311.
9. Meirelles Lda S, Fontes AM, Covas DT, Caplan AI. Mechanisms involved in the therapeutic properties of mesenchymal stem cells. Cytokine Growth Factor Rev. 2009;20:419-27.
10. Coleman CM, Curtin C, Barry FP, O'Flatharta C, Murphy JM. Mesenchymal stem cells and osteoarthritis: remedy or accomplice? Hum Gene Ther. 2010;21:1239-50.
11. Murphy JM, Fink DJ, Hunziker EB, Barry FP. Stem cell therapy in a caprine model of osteoarthritis. Arthritis Rheum. 2003;48:3464-74.
12. Mokbel AN, El Tookhy OS, Shamaa AA, Rashed LA, Sabry D, El Sayed AM. Homing and reparative effect of intra-articular injection of autologus mesenchymal stem cells in osteoarthritic animal model. BMC Musculoskelet Disord. 2011;12:259.
13. Bulman SE, Barron V, Coleman CM, Barry F. Enhancing the mesenchymal stem cell therapeutic response: cell localization and support for cartilage repair. Tissue Eng Part B Rev. 2012;19:58-68.
14. Mason C. Stem cells are big news, but are they big business? Med Device Technol. 2005;16:25.
15. Mason C. Regenerative medicine 2.0. Regen Med. 2007;2:11-8.
16. Mason C, Manzotti E. Regenerative medicine cell therapies: numbers of units manufactured and patients treated between 1988 and 2010. Regen Med. 2010;5:307-13.
17. Mauck RL, Wang CC, Oswald ES, Ateshian GA, Hung CT. The role of cell seeding density and nutrient supply for articular cartilage tissue engineering with deformational loading. Osteoarthritis Cartilage. 2003;11:879-90.
18. Issa RI, Engebretson B, Rustom L, McFetridge PS, Sikavitsas VI. The effect of cell seeding density on the cellular and mechanical properties of a mechanostimulated tissue-engineered tendon. Tissue Eng Part A. 2011;17:1479-87.
19. Hansen OM, Foldager CB, Christensen BB, Everland H, Lind M. Increased chondrocyte seeding density has no positive effect on cartilage repair in an MPEG-PLGA scaffold. Knee Surg Sports Traumatol Arthrosc. 2012;21:485-93.
20. Dennis JE, Cohen N, Goldberg VM, Caplan AI. Targeted delivery of progenitor cells for cartilage repair. J Orthop Res. 2004;22:735-41.
21. Sarkar D, Vemula PK, Teo GS, Spelke D, Karnik R, le Wee Y, et al. Chemical engineering of mesenchymal stem cells to induce a cell rolling response. Bioconjug Chem. 2008;19:2105-9.
22. Bouffi C, Thomas O, Bony C, Giteau A, Venier-Julienne MC, Jorgensen C, et al. The role of pharmacologically active microcarriers releasing TGF-beta3 in cartilage formation in vivo by mesenchymal stem cells. Biomaterials. 2010;31:6485-93.
23. Yang Y, Rossi FM, Putnins EE. Ex vivo expansion of rat bone marrow mesenchymal stromal cells on microcarrier beads in spin culture. Biomaterials. 2007;28:3110-20.
24. Khanarian NT, Haney NM, Burga RA, Lu HH. A functional agarose-hydroxyapatite scaffold for osteochondral interface regeneration. Biomaterials. 2012;33:5247-58.
25. Porter JR, Henson A, Ryan S, Popat KC. Biocompatibility and mesenchymal stem cell response to poly(epsilon-caprolactone) nanowire surfaces for orthopedic tissue engineering. Tissue Eng Part A. 2009;15:2547-59.
26. Donkerwolcke M, Burny F, Muster D. Tissues and bone adhesives-historical aspects. Biomaterials. 1998;19:1461-6.
27. Jasti B, Li X, Cleary G. Recent advances in mucoadhesive drug delivery systems. Drug Deliv Polymers, Business Briefing: Pharmatech. 2003:194.
28. Chivers RA, Wolowacz RG. The strength of adhesive-bonded tissue joints. Int J Adhes Adhes. 1997;17:127.
29. Jabbari E, Khandemhosseini A. Biologically-responsive hybrid biomaterials: a reference for material scientists and bioengineers. Singapore: World Scientific Publishing; 2010.
30. Zhu J, Marchant RE. Design properties of hydrogel tissue-engineering scaffolds. Expert Rev Med Devices. 2011;8:607-26.
31. Chae JJ, Mulreany DG, Guo Q, Lu Q, Choi JS, Strehin I, et al. Application of a collagen-based membrane and chondroitin sulfate-based hydrogel adhesive for the potential repair of severe ocular surface injuries. Mil Med. 2014;179:686-94.
32. Simson JA, Strehin IA, Allen BW, Elisseeff JH. Bonding and fusion of meniscus fibrocartilage using a novel chondroitin sulfate bone marrow tissue adhesive. Tissue Eng Part A. 2013;19:1843-51.
33. Yang S, Guo Q, Shores LS, Aly A, Ramakrishnan M, Kim GH, et al. Use of a chondroitin sulfate bioadhesive to enhance integration of bioglass particles for repairing critical-size bone defects. J Biomed Mater Res A. 2015;103:235-42.
34. Simson J, Crist J, Strehin I, Lu Q, Elisseeff JH. An orthopedic tissue adhesive for targeted delivery of intraoperative biologics. J Orthop Res. 2012;31:392-400.
35. Sharma B, Fermanian S, Gibson M, Unterman S, Herzka DA, Cascio B, et al. Human cartilage repair with a photoreactive adhesive-hydrogel composite. Sci Transl Med. 2013;5:167ra6.
36. Caplan AI. Why are MSCs therapeutic? New data: new insight. J Pathol. 2009;217:318-24.
37. Leathers TD. Biotechnological production and applications of pullulan. Appl Microbiol Biotechnol. 2003;62:468-73.
38. Rekha MR, Sharma CP. Pullulan as a promising biomaterial for biomedical applications: a perspective. Trends Biomater Artif Organs. 2007;20:116-21.
39. Akiyoshi K, Kobayashi S, Shichibe S, Mix D, Baudys M, Kim SW, et al. Self-assembled hydrogel nanoparticle of cholesterol-bearing pullulan as a carrier of protein drugs: complexation and stabilization of insulin. J Control Release. 1998;54:313-20.
40. Gundersen HJG, Bagger P, Bendtsen TF, Evans SM, Korbo L, Marcussen N, et al. The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis, review article. APMIS. 1988;96:857-81.
41. Garcia Y, Breen A, Burugapalli K, Dockery P, Pandit A. Stereological methods to assess tissue response for tissue-engineered scaffolds. Biomaterials. 2007;28:175-86.
42. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
43. Sato K, Yang XL, Yudate T, Chung JS, Wu J, Luby-Phelps K, et al. Dectin-2 is a pattern recognition receptor for fungi that couples with the Fc receptor gamma chain to induce innate immune responses. J Biol Chem. 2006;281:38854-66.
44. Saijo S, Iwakura Y. Dectin-1 and Dectin-2 in innate immunity against fungi. Int Immunol. 2011;23:467-72.
45. Robinson MJ, Osorio F, Rosas M, Freitas RP, Schweighoffer E, Gross O, et al. Dectin-2 is a Syk-coupled pattern recognition receptor crucial for Th17 responses to fungal infection. J Exp Med. 2009;206:2037-51.
46. Alberts B, Bray D, Lewis J, Raff M, Roberts K, Watson JD. Molecular biology of the cell. New York & London: Garland Publishing; 1994.
47. Pratt CW, Cornely K. Essential biochemistry. Hoboken, NJ: Wiley International; 2004.
48. Bae H, Ahari AF, Shin H, Nichol JW, Hutson CB, Masaeli M, et al. Cell-laden microengineered pullulan methacrylate hydrogels promote cell proliferation and 3D cluster formation. Soft Matter. 2011;7:1903-11.
49. Abbasi AM, Chester KA, Talbot IC, Macpherson AS, Boxer G, Forbes A, et al. CD44 is associated with proliferation in normal and neoplastic human colorectal epithelial cells. Eur J Cancer. 1993;29A:1995-2002.
50. Khaldoyanidi S, Denzel A, Zoller M. Requirement for CD44 in proliferation and homing of hematopoietic precursor cells. J Leukoc Biol. 1996;60:579-92.
51. Trochon V, Mabilat C, Bertrand P, Legrand Y, Smadja-Joffe F, Soria C, et al. Evidence of involvement of CD44 in endothelial cell proliferation, migration and angiogenesis in vitro. Int J Cancer. 1996;66:664-8.
52. Kaya G, Rodriguez I, Jorcano JL, Vassalli P, Stamenkovic I. Selective suppression of CD44 in keratinocytes of mice bearing an antisense CD44 transgene driven by a tissue-specific promoter disrupts hyaluronate metabolism in the skin and impairs keratinocyte proliferation. Genes Dev. 1997;11:996-1007.
53. Nakamura Y, Muguruma Y, Yahata T, Miyatake H, Sakai D, Mochida J, et al. Expression of CD90 on keratinocyte stem/progenitor cells. Br J Dermatol. 2006;154:1062-70.
54. Ishiura Y, Kotani N, Yamashita R, Yamamoto H, Kozutsumi Y, Honke K. Anomalous expression of Thy1 (CD90) in B-cell lymphoma cells and proliferation inhibition by anti-Thy1 antibody treatment. Biochem Biophys Res Commun. 2010;396:329-34.
55. Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M. Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. Oncogene. 2003;22:6557-63.
56. Stagg J, Divisekera U, Duret H, Sparwasser T, Teng MW, Darcy PK, et al. CD73-deficient mice have increased antitumor immunity and are resistant to experimental metastasis. Cancer Res. 2011;71:2892-900.
57. Yegutkin GG, Marttila-Ichihara F, Karikoski M, Niemela J, Laurila JP, Elima K, et al. Altered purinergic signaling in CD73-deficient mice inhibits tumor progression. Eur J Immunol. 2011;41:1231-41.
58. Zhang Y, Yang Y, Hong H, Cai W. Multimodality molecular imaging of CD105 (Endoglin) expression. Int J Clin Exp Med. 2011;4:32-42.
59. Bavaresco L, Bernardi A, Braganhol E, Cappellari AR, Rockenbach L, Farias PF, et al. The role of ecto-5′-nucleotidase/CD73 in glioma cell line proliferation. Mol Cell Biochem. 2008;319:61-8.
60. Li YM, Schilling T, Benisch P, Zeck S, Meissner-Weigl J, Schneider D, et al. Effects of high glucose on mesenchymal stem cell proliferation and differentiation. Biochem Biophys Res Commun. 2007;363:209-15.
61. Saijo S, Ikeda S, Yamabe K, Kakuta S, Ishigame H, Akitsu A, et al. Dectin-2 recognition of alpha-mannans and induction of Th17 cell differentiation is essential for host defense against Candida albicans. Immunity. 2010;32:681-91.
62. Tilg H, Trehu E, Atkins MB, Dinarello CA, Mier JW. Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood. 1994;83:113-8.
63. Haynesworth SE, Baber MA, Caplan AI. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J Cell Physiol. 1996;166:585-92.
64. Majumdar MK, Thiede MA, Mosca JD, Moorman M, Gerson SL. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol. 1998;176:57-66.
65. Xing Z, Gauldie J, Cox G, Baumann H, Jordana M, Lei XF, et al. IL-6 is an antiinflammatory cytokine required for controlling local or systemic acute inflammatory responses. J Clin Invest. 1998;101:311-20.
66. Hung SC, Pochampally RR, Chen SC, Hsu SC, Prockop DJ. Angiogenic effects of human multipotent stromal cell conditioned medium activate the PI3K-Akt pathway in hypoxic endothelial cells to inhibit apoptosis, increase survival, and stimulate angiogenesis. Stem Cells. 2007;25:2363-70.
67. Pelletier JP, Caron JP, Evans C, Robbins PD, Georgescu HI, Jovanovic D, et al. In vivo suppression of early experimental osteoarthritis by interleukin-1 receptor antagonist using gene therapy. Arthritis Rheum. 1997;40:1012-9.
68. Wong VW, Rustad KC, Glotzbach JP, Sorkin M, Inayathullah M, Major MR, et al. Pullulan hydrogels improve mesenchymal stem cell delivery into high-oxidative-stress wounds. Macromol Biosci. 2011;11:1458-66.
69. Singh RS, Ganganpreet KS. Pullulan: Microbial sources, production and applications. Carbohydr Polym. 2008;73:515-31.